Orally administered lenalidomide, a second-generation antimyeloma thalidomide analog, is a workhorse in contemporary management of multiple myeloma: it is approved by the US Food and Drug Administration (FDA) for the posttransplantation treatment of newly diagnosed multiple myeloma and for postinduction maintenance therapy for patients who are not eligible for autologous stem cell transplantation (ASCT).1,2 Recently, reported findings from the randomized phase 3 Myeloma XI clinical trial bolster the case for lenalidomide’s central role in the management of multiple myeloma.1
“Lenalidomide was proven beneficial and has taken the slot as an indispensable agent in the initial antimyeloma regimens,” noted Ajay Nooka, MD, MPH, FACP, associate professor, hematology and medical oncology, the Emory University School of Medicine, and the Winship Cancer Institute of Emory University, Atlanta, Georgia. “It has more potent antimyeloma activity and a more favorable toxicity profile, relative to its parent compound.”
Read more at: https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-lenalidomide-maintenance-therapy/article/830286/